Tarsus Pharmaceuticals/$TARS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Ticker
$TARS
Sector
Primary listing
Employees
323
Headquarters
Website
TARS Metrics
BasicAdvanced
$3.2B
-
-$2.31
0.79
-
Price and volume
Market cap
$3.2B
Beta
0.79
52-week high
$75.01
52-week low
$35.84
Average daily volume
720K
Financial strength
Current ratio
5.257
Quick ratio
4.891
Long term debt to equity
21.686
Total debt to equity
21.781
Interest coverage (TTM)
-10.65%
Profitability
EBITDA (TTM)
-96.418
Gross margin (TTM)
73.40%
Net profit margin (TTM)
-31.13%
Operating margin (TTM)
-33.18%
Revenue per employee (TTM)
$910,000
Management effectiveness
Return on assets (TTM)
-14.06%
Return on equity (TTM)
-31.46%
Valuation
Price to revenue (TTM)
10.087
Price to book
9.51
Price to tangible book (TTM)
9.74
Price to free cash flow (TTM)
-33.946
Free cash flow yield (TTM)
-2.95%
Free cash flow per share (TTM)
-2.208
Growth
Revenue change (TTM)
254.45%
Earnings per share change (TTM)
-47.20%
3-year revenue growth (CAGR)
157.08%
3-year earnings per share growth (CAGR)
-3.96%
What the Analysts think about TARS
Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.
Bulls say / Bears say
Tarsus delivered record net product sales of $102.7 million in Q2 2025, representing a 152% year-over-year increase.
XDEMVY coverage now surpasses 90% of commercial, Medicare, and Medicaid lives, supporting broad patient access.
As of March 31, 2025, Tarsus held about $408 million in cash and cash equivalents following a $135 million public equity offering, reflecting a strong balance sheet.
Tarsus applied a gross-to-net discount of about 47% in Q1 2025, which could put pressure on net revenue margins.
Cost of sales rose to $6.2 million in Q2 2025 from $3.0 million a year ago, reflecting increased manufacturing and royalty expenses.
Research and development expenses climbed to $14.4 million in Q1 2025, up 19% year-over-year, indicating higher investment in the pipeline and increased cash burn.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
TARS Financial Performance
Revenues and expenses
TARS Earnings Performance
Company profitability
TARS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tarsus Pharmaceuticals stock?
Tarsus Pharmaceuticals (TARS) has a market cap of $3.2B as of October 16, 2025.
What is the P/E ratio for Tarsus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of October 16, 2025.
Does Tarsus Pharmaceuticals stock pay dividends?
No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Tarsus Pharmaceuticals dividend payment date?
Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.
What is the beta indicator for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.